In the present study, we have identified that cardamonin inhibits oxazolone-induced atopic dermatitis in vivo by inhibiting the production of Th2 cytokines and subsequent oxidative damages through the induction of NRF2. The gene discussed is NFE2L2; the disease is atopic eczema.